FDA issues complete response letter to Leo Pharma's tralokinumab
Leo Pharma's plans to soon launch dermatitis drug tralokinumab in the US were halted on Thursday, since the FDA has rejected the firm's application for marketing authorization and asks for more data on the injection pen that the drug is packaged in.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Less than a week after the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) approved Leo Pharma's drug tralokinumab, the US Food and Drug Administration (FDA) has arrived at the opposite conclusion in the form of a complete response letter.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
CHMP recommends eight medicines for approval
For subscribers
.jpg&w=384&q=75)
